

جدول شماره ۱: Mab های موجود در بازار جهانی

تعداد = ۶۳ عدد

| NO. | MAB                 | COMPANY                  |
|-----|---------------------|--------------------------|
| 1   | Abciximab           | RELIANCE-Janssen Biotech |
| 2   | Adalimumab          | LONZA                    |
| 3   | ATG                 | Sanofi-aventis           |
| 4   | Belimumab           | GlaxoSmithKline/GSK      |
| 5   | Bevacizumab         | ROCHE                    |
| 6   | Blinatumomab        | AMGEN                    |
| 7   | Brentuximab vedotin | Seattle Genetics         |
| 8   | Canakinumab         | NOVARTIS                 |
| 9   | Efalizumab          | GENETECH- MERCK          |
| 10  | Cetuximab           | MeRCK                    |
| 11  | Daratumumab         | JANSSEN BIOTECH          |
| 12  | Denosumab           | Amgen-AMGEN              |
| 13  | Eculizumab          | ALEXION PHARMACEUTICAL   |

|    |                 |                                   |
|----|-----------------|-----------------------------------|
| 14 | Elotuzumab      | BRISTOL- MYER                     |
| 15 | Etanercept      | PFIZER+AMGEN/أريوزن               |
| 16 | Golimumab       | JNJ+MERCK                         |
| 17 | Infliximab      | JANSSEN BIOTECH/ PFIZER/CELLTRION |
| 18 | Ipilimumab      | Bristol-Myers                     |
| 19 | Itolizumab      | BIOCON                            |
| 20 | Muromonab(OKT3) | Janssen - cilag                   |
| 21 | Monolizumab     | STADA                             |
| 22 | Natalizumab     | BIOGEN IDEC                       |
| 23 | Necitumumab     | ELI LILLY                         |
| 24 | Nimotuzumab     | BIOCON                            |
| 25 | Nivolumab       | BRISTOL- MYER                     |
| 26 | Obinutuzumab    | ROCHE                             |
| 27 | Ofatumumab      | GLAXOSmithKline                   |
| 28 | Omalizumab      | GENETECH                          |

|    |                          |  |
|----|--------------------------|--|
| 29 | Palivizumab              | ASTERAZENECA                                   |
| 30 | Panitumumab              | AMGEN  |
| 31 | Pembrolizumab            | MERCK  |
| 32 | Pertuzumab               | ROCHE  |
| 33 | Ramucirumab              | ELI LILLY                                      |
| 34 | Ranibizumab              | NOVARTIS /GENTECH/ BIOMED/ROCHE                |
| 35 | Rituximab                | ROCHE/DR.REDDY/INTAS/RELIANCE/ اریوژن / سیناژن |
| 36 | Secukinumab              | NOVARTIS                                       |
| 37 | Tocilizumab              | ROCHE  |
| 38 | Trastuzumab              | ROCHE/BIOCON/ROCHE/ اریوژن + کوثر              |
| 39 | Ado-trastuzumab-emtansin | ROCHE  |
| 40 | Ustekinumab              | JOHNSON & JOHNSON                              |
| 41 | Raxibacumab              | Human Genome Sciences                          |
| 42 | Satumomab                | Cytogen  |
| 43 | Nofetumomab              | Boehringer Ingelheim/ neorex                   |

|    |                       |                 |
|----|-----------------------|-----------------|
| 44 | Imiciromab            | CENTOCOR        |
| 45 | Capromab              | CYTOGEN         |
| 46 | Arcitumomab           | IMMUNOMEDICS    |
| 47 | Sulesomab             | IMMUNOMEDICS    |
| 48 | Daclizumab            | ROCHE           |
| 49 | Basiliximab           | NOVARTIS        |
| 50 | Votumumab             | ORGANON TEKNICA |
| 51 | Gemtuzumab ozogamicin | WYETH           |
| 52 | Alemtuzumab           | MILLENNIUM      |
| 53 | Ibritumomab tiuxetan  | BIOGEN IDEC     |
| 54 | Tositumomab           | CORIXA& GSK     |
| 55 | Fanolesomab           | PALATIN         |
| 56 | Catumaxomab           | VIVENTIA        |
| 57 | Certolizumab pegol    | UCB             |
| 58 | Catumaxomab           | FRESENIUS       |

|           |              |                                 |
|-----------|--------------|---------------------------------|
| <b>59</b> | Besilesomab  | CIS BIO                         |
| <b>60</b> | Raxibacumab  | HGS                             |
| <b>61</b> | Dinutuximab  | UNITED THERAPEUTICS CORPORATION |
| <b>62</b> | Siltuximab   | JANSSEN BIOTECH                 |
| <b>63</b> | Idarucizumab | INGELHEIM PHARMACEUTICAL        |